Biomarkers Associated with Checkpoint Inhibitors
Cet article passe en revue les travaux récents sur l'identification de biomarqueurs susceptibles de prédire l'efficacité et la toxicité des traitements à base d'inhibiteurs de point de contrôle immunitaire, principalement les anticorps anti CTLA4 et anti PD1/PD-L1
Checkpoint Inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients.
Annals of Oncology , article en libre accès, 2016